Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 83

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 83
---
 3. | Rabbit Model – Infective Endocarditis |

A rabbit model of MRSA endocarditis was employed using 2.2–2.5 kg New Zealand white rabbits. Animals were infected with ~10⁵ CFU MRSA (MW2 strain) and randomized (n=8 per group) into three groups: Nano-Mupirocin (25 mg/kg IV BID), free mupirocin (same dose), or saline control. After 3 days of treatment, animals were euthanized, and bacterial counts were determined in vegetations, kidneys, and spleen. Nano-Mupirocin-treated animals showed statistically significant reductions in bacterial counts across all tissues compared to controls.

| Figure 3: Rabbit survival. Percent survival of             
 rabbits in endocarditis study across the treatment groups. |     | Figure 4: Rabbit PK Profile. Mupirocin plasma                                         
 concentrations after IV administration of 25 mg/kg Nano-mupirocin vs. free mupirocin. |

Reference: Ahuva Cern, Ayelet Michael-Gayego, Yaelle Bavli, Erez Korena, Amiram Goldblum, Allon E. Moses, Yan Q. Xiong and Yechezkel Barenholz* Nano-mupirocin: enabling the parenteral activity of mupirocin DOI 10.1515/ejnm-2016-0006

<div align='center'>50</div>

| 4. | Murine Model                                     
 – Necrotizing Fasciitis (Streptococcus pyogenes) |

A dose–response study was conducted
in a mouse model of necrotizing fasciitis using group A Streptococcus (GAS). Mice (n=6 per group) received a single IV dose of Nano-Mupirocin
(1.1–57 mg/kg) one hour post-infection. Survival was monitored for 5 days. All untreated mice died within 48 hours. Complete survival
was observed at doses ≥11 mg/kg, with a clear dose-dependent protection from mortality and clinical symptoms.

| Figure                                                                                    
 5. Dose response to Nano-mupirocin in a murine necrotizing fasciitis model.               
 Figure                                                                                    
 6: Mortality during the study and disease parameters (rough hair and wound development)   
 48 h after the bacterial challenge. (A) A study to compare one prophylactic dose of